ADMA Biologics Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong earnings and margin expansion, with ASCENIV revenue up 28% year-over-year and BIVIGAM down 54% amid industry oversupply and aggressive discounting. ASCENIV fundamentals remain robust, and 2026 guidance reflects continued growth despite competitive pressures.
-
Revenue exceeded $510 million in 2025, with strong EBITDA and net income growth. Yield enhancement and ASCENIV market penetration are driving margin expansion, while divestiture of plasma centers and new supply contracts optimize operations. Pipeline progress and facility expansion support long-term growth.
Fiscal Year 2025
-
Revenue grew 20% to $510M in 2025, driven by Asceniv's 51% growth and margin expansion. 2026 guidance forecasts revenue above $635M, with continued margin and cash flow improvements, supported by yield-enhanced production and expanded plasma supply.
-
Record Q3 2025 results with 12% revenue growth and expanding margins, led by ASCENIV's strong demand and improved payer access. Guidance for 2025 and 2026 raised, with yield-enhanced production and robust supply chain supporting long-term growth.
-
Q2 2025 saw strong revenue and margin growth, driven by record ASCENIV utilization, a 20%+ IG yield boost from a new FDA-approved process, and robust cash flow. Guidance for 2025 and 2026 was reaffirmed, with significant margin expansion and a $1.1B+ revenue target by 2030.
-
Q1 2025 saw 40% revenue growth, margin expansion, and strong demand for ASCENIV, supported by FDA approval of a yield enhancement process. Guidance for 2025 and 2026 was raised, a $500M share repurchase was authorized, and the business remains insulated from global trade risks.
-
Specialty plasma-derived biologics producer is seeing strong demand for its differentiated immunoglobulin product, Asceniv, and has expanded plasma supply contracts to support growth. Conservative guidance was raised for 2025–2026, with further upside possible from yield enhancements and new pipeline products.
-
A vertically integrated U.S. immunoglobulin producer is expanding plasma sourcing and manufacturing efficiency, targeting $1B+ revenue by 2030. High-margin ASCENIV drives growth, with new supply contracts and yield enhancement initiatives expected to accelerate profitability.
Fiscal Year 2024
-
2024 saw 65% revenue growth and a major margin expansion, driven by Asceniv's strong demand and new plasma supply contracts. Guidance for 2025 and 2026 was raised, with further upside possible from a pending yield enhancement process.
-
Q3 2024 saw 78% revenue growth and a 1,300% net income increase year-over-year, driven by Asceniv's strong demand and strategic production shifts. Guidance for 2024 and 2025 was raised, with significant margin expansion expected from yield enhancement initiatives.
-
The conference highlighted strong demand and clinical differentiation for ASCENIV, with robust IP protection and a clear path to margin expansion as the product mix shifts. Management projects compounding growth, yield improvements, and a long runway for value creation.
-
Q2 2024 saw record revenue of $107.2M (up 78% YoY), Adjusted EBITDA of $44.5M (+600% YoY), and net income of $32.1M, aided by a one-time accrual reversal. ASCENIV now exceeds 50% of revenue, with 2024 guidance raised above $400M and major yield enhancements pending regulatory approval.
-
The virtual meeting confirmed a quorum and proceeded with the election of Class II directors and the ratification of the independent auditor for 2024. All proposals passed with strong support, and no questions were raised by stockholders.